Faculty ProfilesJune Lee, MD
550 16th. Street
San Francisco, CA 94158
June Lee, MD, is the Director of the Catalyst program at Clinical and Translational Science Institute (CTSI) and a Professor in the School of Medicine at UCSF. A key focus of her work at UCSF is to identify the most compelling discovery research and enabling and supporting the projects towards product and commercialization. She is the chief architect of the highly successful Catalyst Program which serves as an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. She also oversees key strategic partnerships at UCSF to include industry collaborations. Currently, she also serves as Chair of the Drug, Device, Discovery and Development (D4) workgroup of UC BRAID (University of California Biomedical Research Acceleration Integration and Development) and was previously the Vice-Chair of CTSA Translational Key Function Committee.
Prior to UCSF, she worked at Genentech where as the therapeutic area head, she led early clinical development programs in Infectious Diseases, Cardiovascular/Metabolic Diseases, and Respiratory Diseases. In that role, she was responsible for the clinical strategy and execution of programs in the early clinical development stages and successfully developed pre-clinical and late stage research projects in a variety of therapeutic areas through IND clearance and early stage clinical proof of concept studies.
Education and Training
|Location||Degree or Training||Specialty||Date|
|University of California, Davis||M.D.||School of Medicine||1992|
|Johns Hopkins University||B.S.||Chemistry||1988|
Related Web Sites
Recent Articles (14)
Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014 Jan; 44(1):38-46.
Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin a: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012 Jan 08; 14(1):R6.
Campbell JD, Borish L, Haselkorn T, Rasouliyan L, Lee JH, Wenzel SE, Sullivan SD. The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. Eur Respir J. 2008 Nov; 32(5):1237-42.
Peters AT, Klemens JC, Haselkorn T, Weiss ST, Grammer LC, Lee JH, Chen H. Insurance status and asthma-related health care utilization in patients with severe asthma. Ann Allergy Asthma Immunol. 2008 Apr; 100(4):301-7.
Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007 Dec; 132(6):1882-9.
Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, Lee JH. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007 May; 119(5):1156-63.
Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H, Wenzel SE, Weiss ST. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J. 2006 Dec; 28(6):1145-55.
Lee JH, Haselkorn T, Chipps BE, Miller DP, Wenzel SE. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. J Asthma. 2006 Apr; 43(3):179-84.
Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006 Mar; 96(3):406-14.
Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ, Sheppard D. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol. 2001 Oct; 25(4):474-85.